cyrilzakka/clinical-trials huggingface dataset:
A Multicenter Prospective Clinical Study of Endoscopic Foam Sclerotherapy for Internal Hemorrhoids

"Internal hemorrhoid" affects the quality of life due to hemorrhage and prolapse as a common and frequently-occurring disease. Endoscopic sclerosing agent injection has replaced traditional surgery and become the most commonly used treatment method in developed countries. At present, how to reduce the side effects of sclerosing agent and accurately determine the injection site and depth has become a difficult clinical problem. The research group creatively put forward the theory of foam sclerosing agent to treat internal hemorrhoids in the early stage. With the aid of transparent cap, the visibility of surgical field of vision can be improved. The mini probe ultrasound (MPS) is proposed to effectively evaluate the submucosal in


Eligibility Criteria:
Inclusion Criteria:

* People are willing to sign the informed consent form of this trial.
* People(aged 18 to 70 years) with clinical symptoms such as bleedingprolapse and so on have been diagnosed with grade I, grade II and grade III internal hemorrhoids by colonic epdoscopy;
* People can follow short-term (3 month) and long-term (12 month) visit plans;
* Describe symptoms objectively and actively complete the evaluation scale;
* No allergic diseases and allergy to sclerosing drugs;
* Non-lactating and pregnant women: patients without pregnancy plan (including the men) in 1 month after the test;
* Did not participate in any drug trials (including this trial drug) within 3 months before the trial;
* People with long-term use of anticoagulant drugs (such as aspirin, clopidogrel, etc.) need to be stopped for 5-7 day

Exclusion Criteria:

* People with severe insufficiency of heart, brain, lung and other organs, leading to inability to tolerate endoscopic treatment;
* People with drug allergies or abnormal blood coagulation function;
* People suffering from or combined with digestive tract diseases,such as the colon malignancyulcerative colitis or Crohn's diseaseacute diarrheaacute thrombotic internal hemorrhoids with painanal fistulaanal fissurefecal incontinence
* Men with history of severe prostate hypertrop;
* People with any reasons that the researchers believe can not be selected
Diet and Physical Activity Interactions in Obesity

The projects funded by this grant, primarily focus on environmental factors that promote weight-gain in the general human population, and how to modify these factors, to prevent further weight-gain in the future. In the coming years, the researchers at the University of Colorado-HSC hope to gain an understanding as to how small changes in diet and physical activity can be achieved and sustained to prevent weight-gain.


Eligibility Criteria:
* BMI: 21-26
* \< 5lb. weight change in 6 mo.
* usual fat intake 25-35%
* regularly eats 3 meals/day
* no chronic health problems known to affect appetite
* either active or inactive (specific criteria do exist)
* no smoking
* women must be on bcps
* no evidence of depression, eating disorder, or restrained eater (determined from validated questionnaires).
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer

Real-World Effectiveness of Regorafenib in the Treatment of Patients with Metastatic Colorectal Cancer- A Retrospective, Observational Study

To analyze the real-world usage pattern, effectiveness and factors associated with the effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer (mCRC). This retrospective, observational study included clinicopathological and follow-up data of patients with mCRC who were treated with regorafenib from June 2017 to September 2020. Patients with incomplete data were excluded. Overall survival (OS) stratified by combination therapy with programmed cell death ligand-1 (PD-L1) inhibitors, chemotherapy and regorafenib dose was calculated by Kaplan Meier method and log rank test. R software version 4.0 was used for the analysis.

Eligibility Criteria:
1. Inclusion Criteria:

   1. Must be a pathologically proven colorectal adenocarcinoma
   2. Must have been treated with regorafenib
   3. Regorafenib must be used after two lines of standard antitumor therapy
2. Exclusion Criteria:

   1. Application is less than one course of treatment with regorafenib
   2. First - or second-line treatment with regorafenib
   3. Patients with multiple primary cancers
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.


Eligibility Criteria:
Inclusion Criteria:

* Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant
* No more than 3 prior chemotherapy regimens in the metastatic setting
* Must have at least one target lesion that is radiographically measurable
* Good performance status
* No history of or current brain or leptomeningeal disease
Validation of Brain Function Assessment Algorithm for mTBI/Concussion in College Athletes

This study is Part 1 of data collection from 18-25 years old subject population for validation of previously derived algorithms. This data will be combined with that collected under NCT03671083 (Part 2 with subject age range 13-25 years) for the final analyses of validation of the algorithms.

EEG, neurocognitive performance and clinical data will be collected at time of injury (within 3 days) at clinically determined Return to Play (RTP) and 45 days after RTP, for the purpose of independently validating the performance of the algorithms developed in prior studies (NCT02477943, NCT02661633 and NCTXXXXXX). Data collected under this study will be combined with that collected under NCT03671083 for the final analyses of prospective algorithm performance in an independent population ages 13-25 years. Subjects will come from the sports and other populations of concussed individuals. They will be matched with controls i.e. not head injured subjects who will also undergo the same set of tests and the same time intervals as the injured subjects. An additional pool of uninjured (not head injured) subjects will be collected who will be assessed at a single time point.

Eligibility Criteria:
Inclusion Criteria (For Injured Subjects):

1. Time of injury within 72 hours of BrainScope Battery
2. No evidence of abnormality visible on Computerized Tomography (CT) of the head related to the traumatic event (Note: neuroimaging is not required for enrollment)
3. No hospital admission due to either head injury or collateral injuries for \>24 hours
4. GCS between 13-15

Exclusion Criteria:

1. Previously enrolled as an Injured or Matched Control subject in the BrainScope Algorithm Development Study
2. Current CNS active prescription medications taken daily, with the exception of medications being taken for the treatment of Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD)
3. Forehead, scalp or skull abnormalities that prevents headset application or EEG data collection
4. History of brain surgery or neurological disease
5. Pregnant women
6. Do not speak or read English
7. Loss of consciousness ≥ 20 minutes related to the concussion injury - for injured subjects only
8. Prior history of concussion in the last year - for Matched Control subjects only
Nutrition Education Program for Postoperative Patients With Gastric Cancer

Using randomized control study, explore the effect of standardized nutrition education program on the nutrition status and life quality of patients with gastric cancer after surgery.


Eligibility Criteria:
Inclusion Criteria:

* Patients are diagnosed with gastric cancer and receive operation.
* Patients need nutrition support treatment
* Informed consent.

Exclusion Criteria:

* Critical patients or stage IV
* Patients with severe hepatic cirrhosis, Chronic Obstructive Pulmonary Disease, chronic renal failure, intestinal obstruction, stroke.
* Unconscious or psychiatric patients
* Patients with communication problems
Positive Pregnancy Program

The Positive Pregnancy Program is an innovative, unique, interprofessional model of care for HIV-positive pregnant women. This program has been in place at St. Michael's Hospital for five years. This study is important because it will allow for a critical evaluation of the Program, and to identify strengths and weaknesses. This will in turn provide the opportunity to improve delivery of care for HIV positive women.

The aim of the P3 program is to provide supportive and comprehensive care from a variety of perspectives, including medical, social, and psychological. The premises on which the program are built include: a commitment to the respect, confidentiality, dignity and medical care of clients; health promotion; normalizing the care of HIV-positive pregnant women; knowledge translation; and the intentions to build a model of care that is transferable to other clinicians and to other conditions.

During antenatal visits, pregnant women are seen by a multidisciplinary team of professionals including an Obstetrician, Midwife, Prenatal Nurse and Social Worker. Different rooms are used for routine antenatal care maneuvers and for consultation and counseling. The Midwife attends the births of the women in the program, and does home post partum care visits. Care is provided that is patient- and family-centered. Partners are invited to attend as many visits as the couple wishes. Because of this team approach, significantly more time is spent with each woman than would occur at a routine prenatal visit.

The patient population at the St. Michael's clinic is largely made up of immigrant women. Many of these women are refugees, and have fled conflict zones or wars to come to Canada. More than 50% have lived in Canada for less than five years. Many of these women are marginalized, and may not access care elsewhere. They have many issues beyond HIV, and some of the social determinants of health that we observe during their time in the program include issues surrounding housing, finance, immigration, legal issues, social support, co-morbid conditions and substance use.

Since the launch of the program, there has been a rapid increase in the number of women attending each year. The program has also attracted significant attention, both from within the medical and health care communities and beyond.

This study seeks to determine if women cared for in the Positive Pregnancy Program will have a high degree of satisfaction with this model of care.

Eligibility Criteria:
Inclusion Criteria:

* HIV positive pregnant women who took part in P3 program

Exclusion Criteria:

* HIV negative
* did not take part in P3 program
Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery

The purpose of this study is to evaluate the effects of continuous local anesthetic delivery on the immediate post-op recovery of patients undergoing spinal fusion surgery for congenital or idiopathic scoliosis.

Constant local analgesic infusion is a relatively new modality that provides a constant supply of medication without the need for repeat injections. This method has shown encouraging results with respect to pain levels, narcotic use, faster rehabilitation and shorter hospital stay in patients undergoing laparotomies, iliac crest bone graft harvest, and sternotomies. In addition, there have not been any reported complications when used in these scenarios.

We hope to confirm better pain control, less narcotic use (i.e. PCA), fewer narcotic side effects, better response to physical therapy and earlier discharge. Which may be generalized to the spinal surgery patient population as less pain and suffering and a better overall hospital course

Eligibility Criteria:
Inclusion Criteria:

* Clinical Diagnosis of Congenital Scoliosis
* Clinical Diagnosis of Idiopathic Scoliosis
* Anticipated Spinal Fusion Surgery

Exclusion Criteria:

* Less than 8 years of age
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children

The study aims to evaluate the safety and immunogenicity of the 10-valent and 13-valent pneumococcal conjugate vaccines when administered in an accelerated schedule in Papua New Guinean children, who experience early dense upper respiratory tract colonisation with a broad range of pneumococcal serotypes, and to compare antibody titres following a booster dose of polysaccharide vaccine at 9 months with those children who received no booster at the same age.

The primary aim of the study is to determine whether PCV10 and PCV13 are safe and immunogenic in PNG infants for the serotypes in the respective vaccines. This study is important for the following reasons:

1. There is a lack of data worldwide on immunogenicity in populations with very high early onset of dense URT carriage.
2. The EPI immunisation schedule is very accelerated in PNG (ages 1,2 and 3 months).
3. There are not data on functional antibody to PCVs in PNG.
4. There are no data on NTHi Protein D antibody responses in PNG and worldwide in population with very high URT carriage rates from a young age, i.e. those most likely to benefit from a vaccine including NTHi protein carrier.
5. It is important to investigate impact of vaccine on carriage density in view of our finding of limited impact of 7vPCV on URT carriage.
6. There is no data on antibody responses following 10v or 13v PCV to booster with PPV as young as 9 months of age (which would be the most appropriate within the current PNG EPI schedule and in the many other third world countries).
7. There is no data on antibody responses (including functional assays) to 23vPPV challenge at age 2 years after 23vPPV booster at age 9 months in children primed with PCV.
8. The broad range of serotypes causing IPD in PNG necessitates continuing consideration of 23vPPV as a potential booster at age 9 months.
9. Serotype-specific B cell memory is an important aspect that we can now test to address immunological safety of PPV in children primed with PCV.
10. The Global Alliance for Vaccines and Immunisation (GAVI) and the World Health Organisation (WHO) have committed to the introduction of PCV for infants in GAVI-eligible countries (including PNG) using novel funding mechanism. In PNG, the introduction of a PCV is planned for 2013.

Eligibility Criteria:
Inclusion Criteria:

* Health infants between 28 - 35 days old

Exclusion Criteria:

* Infants of women not intending to remain in the are for at least two years
* Birth weigh \< 2000 g (2kg)
* Severe congenital abnormalities
* Mother or child known to be HIV positive
Patients' Choice of Health Care Provider for Monitoring Their Pregnancy

The aim of this study is to understand and interpret the determinants that lead pregnant women to refer more to a health professional in order to better meet the patient's request.

Pregnancy is a natural phenomenon that occurs without complication in the majority of pregnant women. Pregnancy monitoring is necessary to detect possible complications and improve the comfort and experience of all pregnant women. For several years now, pregnant women have wanted to benefit from pregnancy monitoring as well as a less medical and physiological delivery according to the perinatal plan 2005-2007.

Perinatal plans have been implemented and evaluated for over 30 years. Progress has been made in terms of obstetrical and perinatal safety. The latest plan advocates a "humanisation of birth" which leaves more room for the parents' wishes. Pregnancy monitoring is currently carried out by doctors or midwives as part of seven compulsory prenatal examinations. This medical follow-up is completed by a preparation for birth with group classes, based on these general and obstetrical assessments.

After declaring their pregnancy, women can consult various health professionals to monitor their pregnancy. The aim of this study is to understand and interpret the determinants that lead pregnant women to be more oriented towards one health professional or another. Each determinant will be analysed and quantified in order to better respond to patient demand. The investigator chose to interview women who had just given birth and not pregnant women because the health professional may change during the course of the pregnancy, and the investigator assumes that the women will have more perspective on their experience and their choice once they have given birth.

Eligibility Criteria:
Inclusion Criteria :

* Woman in post-natal care at the NOVO hospital - Pontoise site
* Women aged 18 and over

Exclusion Criteria :

* Women who do not speak or understand French language (written and oral)
* Woman under legal protection (guardianship, curatorship...)
* Refusal to participate
Transcutaneous Measurement of Jaundice in the Newborn

Prospective comparison of measurement of bilirubin in jaundiced newborns by a transcutaneous device (bilirubinometer) and laboratory analysis of blood samples.

We hypothesise that correlation of the two measurements depend on bilirubin level, gestational age as well as postnatal age.

Whenever a blood sample is drawn for measurement of bilirubin in a newborn, a transcutaneous measurement of skin yellow color will be made. Such measurements will also be included in all infants when a CRP-test (blood sample for C-reactive protein) has been ordered, as well as in connection with the routine blood sampling for metabolic screening. Only infants where parents have given written consent for their infant will be included in the study.

Eligibility Criteria:
Inclusion Criteria:

* Newborn infant admitted to normal newborn nursery

Exclusion Criteria:

* Informed consent not obtained
Preventing Preterm Birth With a Pessary

The primary objective of this study, is to determine the effect of a Cup pessary, a device that is currently readily available in the USA and similar in design to the Arabin pessary, on the incidence of delivery prior to 37 weeks in women with a history of prior spontaneous birth (before 37 weeks) and incidentally found to have a cervix less than 25 mm in length prior to 23 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Singleton pregnancies in patients with a history of spontaneous preterm birth (previous delivery between 17 0/7 weeks and 36 6/7 weeks).
* Women ages 18 to 45 years of age

Exclusion Criteria:

* Major fetal abnormalities (defined as those that are lethal or require prenatal or postnatal surgery), fetal death, or fetal growth restriction diagnosed before randomization.
* Presence of prophylactic cervical cerclage
* Significant maternal-fetal complications (treated chronic hypertension, insulin dependant diabetes mellitus, red cell isoimmunization)
* Painful regular uterine contractions, or ruptured membranes
* Visual cervical dilation of 2cm or greater and visible membranes.
* Patients with a pregnancy dated by an ultrasound after 20 weeks gestation.
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.


Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016 classification
* Presence of FLT3-ITD and/or D835 mutation(s) in bone marrow or peripheral blood
* Age ≥ 18 years and ≤ 60 years
* Adequate hepatic function within 48 hours prior to induction chemotherapy
* Adequate renal functions within 48 hours prior to induction chemotherapy
* ECOG performance status within 48 hours prior to induction chemotherapy ≤ 3
* Eligible for intensive cytarabine/daunorubicin (7+3) chemotherapy specified

Exclusion Criteria:

* Acute promyelocytic leukemia (APL)
* Known clinically active central nervous system (CNS) leukemia
* Severe liver disease
* Active infections
* Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
* Known infection with human immunodeficiency virus (HIV)
* Prior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)
What do Patients Expect After Scaphoid Fractures?

This study will assess patients expectations pre-op and assess their views on their outcome at one year follow up

Using Trauma expectation factor and trauma outcome measure questionnaire. At fracture time and at one year post fracture

Analyse according to age, sex, fracture pattern, type of intervention

Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of a scaphoid fracture
* Age \> 18
* Consent for one year follow up

Exclusion Criteria:

* Age \<18
* Polytrauma (Multiple systems/ Multiple fractures)
* Ipsilateral fractures of the upper limb that may become distracting or affect rehabilitation
* Delayed presentation with higher risk of non-union or avascular necrosis
A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis

The study will assess the efficacy of OC000459 200 mg twice daily orally in comparison to placebo when subjects are challenged in the Vienna Challenge Chamber for 6 hours. This is a randomised, double blind, placebo controlled, two way crossover evaluation. There will be a screening period of up to three weeks and a washout period of at least one week between the two treatment periods. There will be a follow up one to three weeks after the last dose of study drug.


Eligibility Criteria:
Inclusion Criteria:

* Males aged 18 to 50 years with a history of symptoms of grass pollen related allergic rhinitis within the previous two years.
* Subjects must be free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease as determined by history, physical examination and screening investigations.
* FEV1 within normal limits (≥90% of predicted).
* Atopy defined by a positive cutaneous response to mixed grass pollen within the last 12 months or at screening.
* Asymptomatic at screening
* Non smokers for at least the past 12 months

Exclusion Criteria:

* Medical conditions likely to affect the outcome of the study.
* Nasal conditions likely to affect the outcome of the study, i.e. nasal septal perforations, nasal polyps, sinus disease, chronic nasal obstruction, or other nasal diseases.
* Presence of any respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function
* Immunotherapy treatment course including inhaled or local corticosteroids in the past 28 days.